ArticleHGG advances2026
The AP5B1 p.Leu785Pro variant is a frequent cause of late-onset macular dystrophy with variable extraocular manifestations.
Article in HGG advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
39 authors.
Funding
Abstract
Inherited retinal diseases (IRDs) represent a large group of genetically heterogeneous disorders that often cause progressive visual loss. The fifth adaptor protein (AP-5) complex, which contributes to endolysosomal trafficking and lysosomal homeostasis, has previously been implicated in neurodegenerative syndromes, and more recently, bi-allelic variants in three of its subunits were found in families with macular dystrophy, including four with variants in AP5B1. Here, we describe 22 affected individuals from 20 families with AP5B1-associated IRD, all carrying the recurrent missense variant c.2354T>C (GenBank: NM_138368.5) (p.Leu785Pro), either in the homozygous state (16 families) or in trans with another rare heterozygous AP5B1 missense or loss-of-function variant. Five families were of Ashkenazi Jewish ancestry and 15 families of European ancestry. Clinically, affected individuals presented with a predominantly late-onset macular dystrophy that frequently progressed to cone-rod degeneration. Characteristic retinal findings included foveal sparing, early peripapillary involvement, and a reticular pattern best observed by fundus autofluorescence imaging in the mid- or peripheral retina. The typical presenting symptom was decreased visual acuity. Age at onset ranged from 27 to 74 years, with most individuals becoming symptomatic after the fifth decade of life. Some individuals also presented with extraocular manifestations, most notably hearing loss, which was reported in 8 affected individuals. These findings further support AP5B1 as a cause of macular dystrophy, identify p.Leu785Pro as a relatively frequent pathogenic allele in individuals of European and Ashkenazi Jewish ancestry, and expand the associated phenotypic spectrum to include both isolated macular dystrophy and possible syndromic presentations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.